New Delhi: Drug firm Strides Pharma Science recently said its joint venture (JV) firm has received approval from the US health regulator for Albendazole tablets, used in the treatment of certain infections caused by the tapeworm.
Strides Vivimed Pte Ltd, Singapore, a 50:50 joint venture with Vivimed Labs, has received approval from the United States Food & Drug Administration (US FDA) for Albendazole tablets in the strength of 200 mg, Strides Pharma Science said in a BSE filing.
This is the second generic approval by US FDA for Albendazole tablets, the company added.
Strides Pharma Science said the approved product is a generic version of Amneal Pharmaceuticals Inc’s Albenza tablets.
Quoting IQVIA MAT data, Strides Pharma Science said the US market for Albendazole tablets USP 200 mg is approximately USD 100 million.
Strides Pharma Science Limited(Strides), incorporated in 1990, is a global pharmaceutical Company, headquartered in Bangalore, India. The Company is listed on the Bombay Stock Exchange and National Stock Exchange of India Limited.
Latest posts by MD Team (see all)
- Recordati to seek Canadian approval for kidney disease drug Cystagon - April 17, 2019
- Wockhardt gets zero USFDA observations for Bioequivalence centre - April 16, 2019
- Amgen sets over Rs 15 lakh yearly price for new bone drug Evenity - April 16, 2019